罗氏推出体外针对ROS1突变非小细胞肺癌的诊断测试

2019-06-10 不详 MedSci原创

罗氏诊断公司(Roche Diagnostics)推出了首个针对ROS1阳性肺癌的体外诊断测试VENTANA ROS1(SP384)抗体。该抗体是市场上第一个也是唯一一个在体外通过免疫组化检测ROS1方法,很可能作为一种经济有效的方法来鉴定癌症中ROS1蛋白表达的升高。

罗氏诊断公司(Roche Diagnostics)推出了首个针对ROS1阳性肺癌的体外诊断测试VENTANA ROS1(SP384)抗体。该抗体是市场上第一个也是唯一一个在体外通过免疫组化检测ROS1方法,很可能作为一种经济有效的方法来鉴定癌症中ROS1蛋白表达的升高。

ROS1基因突变存在于2%的非小细胞肺癌NSCLC)患者中,该诊断可以帮助指示哪些患者将对靶向治疗作出应答。通过免疫组化检测ROS1是一种经济有效的方法来鉴定ROS1蛋白表达升高,然后通过另一种方法进行确认,例如荧光原位杂交(FISH)或下一代测序(NGS)。

Roche Diagnostics市场总监Pierre Hazlewood说:"我们高度敏感的ROS1测试是第一个可用于肺癌测试指南推荐的体外诊断测试。ROS1除了在非小细胞肺癌病例中的检测,未来可以应用于其他癌症类型的临床试验中的研究。"

肺癌每分钟导致超过三人死亡,是全世界最常见的癌症,每年估计有210万人被诊断出来。它分为两种主要亚型,即非小细胞肺癌和小细胞肺癌。高达85%的肺癌是非小细胞肺癌NSCLC,可进一步分为腺癌、鳞状细胞癌和大细胞癌。

靶向治疗已经将肺癌治疗从基于组织学的治疗转变为基于致癌突变和融合的治疗。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059811, encodeId=93fb205981139, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jul 12 21:36:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813021, encodeId=7bd1181302178, content=<a href='/topic/show?id=4b6091635c3' target=_blank style='color:#2F92EE;'>#诊断测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91635, encryptionId=4b6091635c3, topicName=诊断测试)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Mon May 18 06:36:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793485, encodeId=af501e9348510, content=<a href='/topic/show?id=e45d15633fc' target=_blank style='color:#2F92EE;'>#ROS1突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15633, encryptionId=e45d15633fc, topicName=ROS1突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Nov 06 08:36:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364495, encodeId=2f6c13644952f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533959, encodeId=8a981533959f7, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15630, encryptionId=0717156309a, topicName=ROS1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0712501452, createdName=wwzzly, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059811, encodeId=93fb205981139, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jul 12 21:36:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813021, encodeId=7bd1181302178, content=<a href='/topic/show?id=4b6091635c3' target=_blank style='color:#2F92EE;'>#诊断测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91635, encryptionId=4b6091635c3, topicName=诊断测试)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Mon May 18 06:36:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793485, encodeId=af501e9348510, content=<a href='/topic/show?id=e45d15633fc' target=_blank style='color:#2F92EE;'>#ROS1突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15633, encryptionId=e45d15633fc, topicName=ROS1突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Nov 06 08:36:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364495, encodeId=2f6c13644952f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533959, encodeId=8a981533959f7, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15630, encryptionId=0717156309a, topicName=ROS1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0712501452, createdName=wwzzly, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2059811, encodeId=93fb205981139, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jul 12 21:36:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813021, encodeId=7bd1181302178, content=<a href='/topic/show?id=4b6091635c3' target=_blank style='color:#2F92EE;'>#诊断测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91635, encryptionId=4b6091635c3, topicName=诊断测试)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Mon May 18 06:36:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793485, encodeId=af501e9348510, content=<a href='/topic/show?id=e45d15633fc' target=_blank style='color:#2F92EE;'>#ROS1突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15633, encryptionId=e45d15633fc, topicName=ROS1突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Nov 06 08:36:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364495, encodeId=2f6c13644952f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533959, encodeId=8a981533959f7, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15630, encryptionId=0717156309a, topicName=ROS1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0712501452, createdName=wwzzly, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2059811, encodeId=93fb205981139, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jul 12 21:36:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813021, encodeId=7bd1181302178, content=<a href='/topic/show?id=4b6091635c3' target=_blank style='color:#2F92EE;'>#诊断测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91635, encryptionId=4b6091635c3, topicName=诊断测试)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Mon May 18 06:36:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793485, encodeId=af501e9348510, content=<a href='/topic/show?id=e45d15633fc' target=_blank style='color:#2F92EE;'>#ROS1突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15633, encryptionId=e45d15633fc, topicName=ROS1突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Nov 06 08:36:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364495, encodeId=2f6c13644952f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533959, encodeId=8a981533959f7, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15630, encryptionId=0717156309a, topicName=ROS1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0712501452, createdName=wwzzly, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=2059811, encodeId=93fb205981139, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jul 12 21:36:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813021, encodeId=7bd1181302178, content=<a href='/topic/show?id=4b6091635c3' target=_blank style='color:#2F92EE;'>#诊断测试#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91635, encryptionId=4b6091635c3, topicName=诊断测试)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Mon May 18 06:36:00 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793485, encodeId=af501e9348510, content=<a href='/topic/show?id=e45d15633fc' target=_blank style='color:#2F92EE;'>#ROS1突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15633, encryptionId=e45d15633fc, topicName=ROS1突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Nov 06 08:36:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364495, encodeId=2f6c13644952f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533959, encodeId=8a981533959f7, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15630, encryptionId=0717156309a, topicName=ROS1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0712501452, createdName=wwzzly, createdTime=Wed Jun 12 10:36:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 wwzzly

相关资讯

2018罗氏诊断亚太心脏标志物研讨会全新热点追踪: 解码心脏生物标志物 守护健康“心”未来

近日,2018罗氏诊断亚太心脏标志物研讨会在上海隆重举行。来自心脏病学、急诊医学和检验医学领域的国内外专家齐聚一堂,围绕心脏标志物的临床应用热点、最新循证研究以及指南中的相关推荐展开深度解读与交流。

罗氏、吉利德、默沙东……跨国公司高管大变动

又到了年底换帅高峰期时,谁将接替吉利德科学 CEO John Milligan的悬念终于被揭晓。

罗氏全球CEO:助力上海,构建具有国际影响力的亚洲医学中心城市

今日,罗氏集团全球首席执行官施万博士(Dr. Severin Schwan)出席第30届上海市市长国际企业家咨询会议(简称IBLAC),并发表题为“构建具有国际影响力的亚洲医学中心城市,树立上海全面深化改革开放的品牌标杆”的主旨演讲,构建以优质的医疗服务与蓬勃发展的生物医学产业集群为核心的亚洲医学中心城市将成为打响上海品牌的核心驱动力。今年,正值上海市市长国际企业家咨询会议30周年,也是施万博士连

罗氏以43亿美元收购基因治疗公司Spark Therapeutics

罗氏以每股114.50美元,总计43亿美元现金收购基因疗法公司Spark Therapeutics,该交易预计将在第二季度完成。

罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准

罗氏的PD-L1单抗Tecentriq(atezolizumab)与化疗药(Abraxane,nab-paclitaxel)联合,用于PD-L1阳性的、无法切除的局部晚期或转移性三阴性乳腺癌(TNBC)患者,通过了FDA的批准测试。

全新抗癌药来了,罗氏全球第三大战略中心明年上海竣工

进博会现场,罗氏制药带来的一款治疗ALK阳性局部晚期或转移性非小细胞肺癌新药——安圣莎,引发了场内外关注。这款新药在美国获批后的9个月便迅速在国内获批,基本实现与欧美同步上市。获批后短短46天,国内第一批经处方开出的安圣莎开始造福患者。“这恰恰生动见证了不断深化改革开放的中国加速度。”上海罗氏制药有限公司总经理周虹在接受文汇报记者专访时这样注解。此次参与首届中国国际进口博览会,罗氏制药高度重视,